Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78, 1966–1986 (2023).

PubMed  Google Scholar 

Venkatesan, N., Doskey, L. C. & Malhi, H. The role of endoplasmic reticulum in lipotoxicity during metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis. Am. J. Pathol. 193, 1887–1899 (2023).

Article  CAS  PubMed  Google Scholar 

Geng, Y., Faber, K. N., de Meijer, V. E., Blokzijl, H. & Moshage, H. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? Hepatol. Int. 15, 21–35 (2021).

Article  PubMed  Google Scholar 

Hoogerland, J. A., Staels, B. & Dombrowicz, D. Immune-metabolic interactions in homeostasis and the progression to NASH. Trends Endocrinol. Metab. 33, 690–709 (2022).

Article  CAS  PubMed  Google Scholar 

Kemper, C. & Sack, M. N. Linking nutrient sensing, mitochondrial function, and PRR immune cell signaling in liver disease. Trends Immunol. 43, 886–900 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huby, T. & Gautier, E. L. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat. Rev. Immunol. 22, 429–443 (2022).

Article  CAS  PubMed  Google Scholar 

Wiering, L., Subramanian, P. & Hammerich, L. Hepatic stellate cells: dictating outcome in nonalcoholic fatty liver disease. Cell Mol. Gastroenterol. Hepatol. 15, 1277–1292 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hammerich, L. & Tacke, F. Hepatic inflammatory responses in liver fibrosis. Nat. Rev. Gastroenterol. Hepatol. 20, 633–646 (2023).

Article  CAS  PubMed  Google Scholar 

Marakovits, C. & Francis, H. Unraveling the complexities of fibrosis and ductular reaction in liver disease: pathogenesis, mechanisms, and therapeutic insights. Am. J. Physiol. Cell Physiol. 326, C698–C706 (2024).

Article  PubMed  Google Scholar 

Zhou, T. et al. Feedback signaling between cholangiopathies, ductular reaction, and non-alcoholic fatty liver disease. Cells 10, 2072 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

He, Y. H., Pan, J. X., Xu, L. M., Gu, T. & Chen, Y. W. Ductular reaction in non-alcoholic fatty liver disease: when Macbeth is perverted. World J. Hepatol. 15, 725–740 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Feng, G. et al. Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 21, 46–56 (2024).

Article  PubMed  Google Scholar 

Ciardullo, S., Vergani, M. & Perseghin, G. Nonalcoholic fatty liver disease in patients with type 2 diabetes: screening, diagnosis, and treatment. J. Clin. Med. 12, 5597 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qadri, S. & Yki-Jarvinen, H. Surveillance of the liver in type 2 diabetes: important but unfeasible? Diabetologia 67, 961–973 (2024).

Article  PubMed  PubMed Central  Google Scholar 

Hutchison, A. L., Tavaglione, F., Romeo, S. & Charlton, M. Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance. J. Hepatol. 79, 1524–1541 (2023).

Article  CAS  PubMed  Google Scholar 

Baumgartner, C., Krssak, M., Vila, G., Krebs, M. & Wolf, P. Ectopic lipid metabolism in anterior pituitary dysfunction. Front. Endocrinol. 14, 1075776 (2023).

Article  Google Scholar 

Dichtel, L. E., Cordoba-Chacon, J. & Kineman, R. D. Growth hormone and insulin-like growth factor 1 regulation of nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 107, 1812–1824 (2022). This is a comprehensive overview of the clinical data that implicate dysregulation of GH and IGF1 in the development and progression of MASLD, and discusses how GH and IGF1 might regulate systemic and liver metabolism to prevent steatosis and liver injury.

Article  PubMed  PubMed Central  Google Scholar 

Takahashi, Y. Nonalcoholic fatty liver disease and adult growth hormone deficiency: an under-recognized association? Best Pract. Res. Clin. Endocrinol. Metab. 37, 101816 (2023).

Article  CAS  PubMed  Google Scholar 

Ichikawa, T. et al. Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiency. Gut 52, 914 (2003).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adams, L. A., Feldstein, A., Lindor, K. D. & Angulo, P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 39, 909–914 (2004).

Article  PubMed  Google Scholar 

Takahashi, Y. et al. Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology 132, 938–943 (2007).

Article  PubMed  Google Scholar 

Nishizawa, H. et al. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. Eur. J. Endocrinol. 167, 67–74 (2012).

Article  CAS  PubMed  Google Scholar 

Lonardo, A., Loria, P., Leonardi, F., Ganazzi, D. & Carulli, N. Growth hormone plasma levels in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 97, 1071–1072 (2002).

Article  PubMed  Google Scholar 

Ichikawa, T. et al. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol. Int. 1, 287–294 (2007).

Article  PubMed  PubMed Central  Google Scholar 

Xu, L. et al. Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study. PLoS ONE 7, e44136 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fusco, A. et al. Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels. Clin. Endocrinol. 77, 531–536 (2012).

Article  CAS  Google Scholar 

Bredella, M. A. et al. Peak growth hormone-releasing hormone-arginine-stimulated growth hormone is inversely associated with intramyocellular and intrahepatic lipid content in premenopausal women with obesity. J. Clin. Endocrinol. Metab. 94, 3995–4002 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dichtel, L. E. et al. The GH/IGF-1 axis is associated with intrahepatic lipid content and hepatocellular damage in overweight/obesity. J. Clin. Endocrinol. Metab. 107, e3624–e3632 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Fellinger, P. et al. Increased GH/IGF-I axis activity relates to lower hepatic lipids and phosphor metabolism. J. Clin. Endocrinol. Metab. 108, e989–e997 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Stanley, T. L. et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA 312, 380–389 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Stanley, T. L. et al. Growth hormone releasing hormone reduces circulating markers of immune activation in parallel with effects on hepatic immune pathways in individuals with HIV-infection and nonalcoholic fatty liver disease. Clin. Infect. Dis. 73, 621–630 (2021).

Article  CAS  PubMed  PubMed Central